First patient enrolled in phase 1/2 “elucidate” trial assessing gtaexs617 in advanced solid tumours

Oxford, england--(business wire)--exscientia plc (nasdaq: exai) today announced that it has enrolled the first patient in its phase 1/2 “elucidate” (gtaexs617-001) study evaluating gtaexs617 (‘617), exscientia's precision-designed cdk7 inhibitor, for the treatment of advanced solid tumours. the clinical trial will evaluate the safety, efficacy and pharmacokinetics of ‘617 across multiple ascending doses in patients with advanced solid tumours including head and neck cancer, colorectal cancer, p.
EXAI Ratings Summary
EXAI Quant Ranking